Spruce (@sprooos) header
Spruce (@sprooos) profile picture

physics @ mit, prev: healthcare @OpenAI, prod

mit
Joined April 2020
Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)Photo by Spruce (@sprooos)
We’ve raised $1B led by @kleinerperkins and @clearlake. We’re still a small team with one goal, to make frontier AI R&D accessible to scientists, researchers and technologists. Join us if it also excites you.
Today we're announcing our $1B Series A, led by @kleinerperkins and @clearlake. We believe making frontier AI R&D more accessible is the most direct path to AI that solves humanity's most pressing problems across science and technology.
46
19
1
385
15,610
AI is running into energy limits, and people are asking whether AI investments will earn back what they cost. That’s exactly why this moment is so exciting. We need to focus on the sectors and workloads that create the most value, and build models and chips that do more with every unit of energy. Really enjoyed working with @JonSaadFalcon, @Avanika15, and the entire team on Joules-to-GDP! Thanks to everyone who helped along the way, especially @Jon_Hartley_, @Azaliamirh, and @HazyResearch.
AI is using more and more of the world’s energy. But how much economic value are we getting from AI? We’re introducing Joules-to-GDP (J2G), a framework that measures how well AI turns energy into economic value and shows which tasks, models, and hardware give the best return. Across 44 occupations in finance, engineering, law, administrative work, and more in @OpenAI's GDPval, we arrive at three findings: 1) The tasks with the highest economic value are not the tasks with the highest economic value per joule. For example, CAD design earns ~10% more per task than building websites, but the latter earns ~27% more value per joule. 2) The most powerful model isn’t always the best use of energy. Gemma 4 31B delivers 56% of GLM 5.2’s net value with 23% of the energy, for 2.5x the value per joule. 3) More chips don’t guarantee proportionate returns. Moving the same model from 1 to 8 NVIDIA H100s uses 3.2x the energy but cuts completion time by only 22%, with about the same value. With @SnorkelAI, we’re also releasing GDPWorks, a benchmark for economically valuable tasks across 36 additional occupations. Joint work co-led by @amirzeinaalii and @Avanika15, with @Mersad_Abbasi, @Jon_Hartley_, John Hennessy, @HazyResearch, and @Azaliamirh. More details below 🧵
23
19
6
67
7,288
Meet Lor: The product we’re building to do the work of an entire AI lab. Remember that one researcher who pretrained Mirendil-Base in 3.5 months, with agents doing nearly all the engineering? That researcher is now fully switched to using Lor 100% of the time.
Meet Lor. We’re building Lor to do the work of an entire AI lab. Today, its agents write our code, run experiments, and iterate on the results for days, on any machine, hundreds at a time. Now in private beta ↓
21
22
4
348
27,389
We discovered and communicated with a Chinese AI agent fleet. We believe this is the first time that researchers have ever made contact with a rogue agent fleet in the wild. Nearly all prior public agent incidents (like the HuggingFace hack) came from American labs. These agents were hosted by Tencent's evaluation research team, and they targeted Alibaba's Amap.
188
733
324
5,858
1,195,023
Spruce retweeted
"reward hacking", an AI alignment term for when your model gets rewarded for doing hacking
4
56
2
707
13,887
32
132
8
2,121
48,294
Spruce retweeted
“If at age 18 you are not an accelerationist, you have no heart. If at age 25 you are not safetyist you have no brain.” something something
50
54
21
1,403
107,415
We are on the cusp of a wave of new therapies for some of the worst diseases. But the world won’t benefit unless the US fixes its drug regulatory system. My new essay for @nytimes, on how slow clinical trials are now the biggest obstacle to curing cancer. nytimes.com/2026/09/04/opini… - I interviewed dozens of researchers, especially oncologists at leading U.S. centers. A striking consensus emerged: science is no longer the main bottleneck to new cancer drugs. It is our ability to test discoveries in patients through clinical trials. - The cost of starting a Phase 1 trial in America has roughly doubled over the past decade. As a result, companies increasingly take early trials abroad: Australia’s Phase 1 trial volume has nearly doubled in a decade, driven mainly by U.S. companies. - Unfortunately, the underlying incentives are badly asymmetric: Institutions can be blamed for harms caused by moving too fast, but almost no one is blamed when patients deteriorate during avoidable delays. One doctor called the emerging system “ritualized safety over actual risk assessment.” Or as, @DavidHongMD put it: "We often forget that the biggest risk is the cancer itself." - This problem is becoming more urgent because medicine itself is changing. Sequencing, biological engineering and A.I. make increasingly personalized therapies possible. But our regulatory system was mostly built for standardized drugs tested in large populations. - @sytse, the co-founder of GitLab, shows what personalized medicine can achieve: after relapsed osteosarcoma and being told there were no options left, he pursued a highly individualized approach and has now been cancer-free for a year. But doing so required extraordinary resources and regulatory expertise. - Pierce Ogden’s father was less lucky. After molecular analysis identified a drug that might target his glioblastoma, the manufacturer agreed to provide it. But administrative barriers delayed access until it was too late. “My dad was ready to try anything,” Pierce told me. “But the system is paternalistic.” - The A.I. revolution is making this bottleneck more important, not less. A.I. relies on relevant data. Information from early-stage trials could compound with A.I. tools to achieve truly revolutionary medicines. Without the data, this is far less likely to happen. - Another important shift is that innovation increasingly comes from academic labs and small biotech companies rather than Big Pharma. These small companies find it far harder to unable to absorb delays and regulatory barriers. - Apart from cancer, China is the biggest winner from America's outdated medical regulations. China has a much faster trial system, with testing often starting a full year earlier. This allows Chinese pharmaceutical companies to experiment and improve medicines while American companies play with mice. Today, half of all drugs licensed by major pharmaceutical companies originate there, up from less than 5 percent only a decade ago. - But we don't need to copy China. The best model is Australia: lots of on-site scientific and ethics reviews, and requirements that are proportionate to small, early-stage trials. Phase 1 studies there begin roughly 6–12 months faster, without any notable increases in adverse safety events. - Operation TrialBlazer, a 2026 HHS initiative is a good start in this direction, but we need legislative action by Congress to truly make Phase I trials faster and more efficient! I want to thank everyone who helped me with this article: everyone I interviewed and the amazing editors at the Times. This is the result of a months long journey of extensive interviews and research. Special thanks go to those who came on the record. One of the features of the system is an atmosphere of fear, where practitioners are afraid to publicly come out and explain these issues. So anyone who does is a hero in my book!
82
415
74
1,610
557,894
Spruce retweeted
this is something i'm very excited about in the ai good ending. human bureaucracies, as they've scaled up, have needed to resort to increasingly systematized and standardized procedures: the human clerk who could make an exception just in this instance, sir is replaced with a click-through software wizard that can't. but in the good ai future, if you have to interact with central coordination mechanisms at all, the ai coordinator can spin up another instance to bargain out your particular situation just as an ai teacher can give your child a personalized learning plan or an ai doctor can spend thousands of subjective hours poring over your personalized medical history. we can finally, for the first time in human history, exit the regime of intelligence starvation and throw off the shackles of standardization.
8
12
2
141
5,781
Replying to @tszzl
1
5
188
18,280
Spruce retweeted
🗣️ 👂 🤐✋
Another major advance vs cancer! @ASCO #ASCO26 Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda) ascopubs.org/doi/10.1200/JCO…
8
107
6
1,080
84,731
Spruce retweeted
We built the lab that's able to go from AI-led drug design to data in 24h. GPT-8 won't be bottlenecked by intelligence. It needs a biological compute layer. This is Capable. We're turning AI capabilities into human capabilities--starting with short-sleeper peptides.
115
137
78
1,472
566,125
Spruce retweeted
We're coming out of stealth. We've built our first racks after a successful A0 tapeout, $1B+ in customer contracts, and $800m raised. Early customer tests show us achieving SOTA throughput, latency, and power efficiency on inference workloads. Our first racks ship this summer.
641
954
614
9,903
6,916,036
We have been heads down but wanted to share a bit about what we are doing 🧵
37
34
17
583
245,125
Computer use models shouldn't learn from screenshots. We built a new foundation model that learns from video like humans do. FDM-1 can construct a gear in Blender, find software bugs, and even drive a real car through San Francisco using arrow keys.
185
390
239
3,916
1,215,222
Spruce retweeted
My favorite paragraph.
20
48
7
583
66,488
Recapping OpenAI’s week in health: 🔹 >230M people use ChatGPT to navigate health each week, across billions of messages 🔹 ChatGPT Health: a dedicated space bringing health intelligence together with your health data, with purpose-built privacy protections 🔹 OpenAI for Healthcare: • ChatGPT for Healthcare: HIPAA-compliant ChatGPT, including trusted medical evidence from millions of studies, reusable health templates/workflows, enterprise controls/governance. Already rolling out to leading institutions–Boston Children’s, Memorial Sloan Kettering, Stanford Children’s, Cedars-Sinai, and more • API for Healthcare: already supports HIPAA and powers the healthcare ecosystem 🔹 All built on the foundation of two years of dedicated research • Rigorous evaluation across both benchmarks (HealthBench) and real-world study (AI clinical copilot) • Every model OpenAI ships today is built for the workflows of consumers and health professionals, across every major stage of model training • We’ve worked in partnership with >260 physicians across 60 countries of practice, dozens of specialties 🔹Today: we’ve acquired Torch, an exceptional, mission-aligned team that will accelerate our roadmap OpenAI’s mission is to ensure AGI benefits all of humanity. We put together a plan for health at OpenAI when I joined 1.5 years ago and have been investing heavily in health since then, because we expect improving health to be one of the defining impacts of AGI. Last week, we completed that original plan–I’m so so proud of our team for running through walls for health impact. ♥️ In 2026 we enter the scaling era for the impact of AI on human health (and scaling is something we’re good at). I hope we can “race to the top” here across labs–in fact, other labs investing heavily here (for the benefit of humanity) is one of our 2026 goals. More from us soon! Learn more: ChatGPT Health: openai.com/index/introducing… OpenAI for Healthcare: openai.com/index/openai-for-… HealthBench: openai.com/index/healthbench… AI clinical copilot study: openai.com/index/ai-clinical…
22
26
2
196
21,225
Incredible News folks
thank you @jtguibas for the rec. standard intuition once again goes up in valuation.
3
1
1
26
7,184
Technological innovation can be a form of participation in the divine act of creation. It carries an ethical and spiritual weight, for every design choice expresses a vision of humanity. The Church therefore calls all builders of #AI to cultivate moral discernment as a fundamental part of their work—to develop systems that reflect justice, solidarity, and a genuine reverence for life.
2,075
4,655
1,547
32,916
5,540,679